Moleculin Biotech Inc (NASDAQ: MBRX) stock fell -3.44% on Friday to $0.59 against a previous-day closing price of $0.61. With 0.19 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.15 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6320 whereas the lowest price it dropped to was $0.5400. The 52-week range on MBRX shows that it touched its highest point at $1.65 and its lowest point at $0.34 during that stretch. It currently has a 1-year price target of $8.00. Beta for the stock currently stands at 1.94.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MBRX was up-trending over the past week, with a rise of 9.26%, but this was down by -4.07% over a month. Three-month performance surged to 7.25% while six-month performance fell -5.98%. The stock lost -42.16% in the past year, while it has lost -44.34% so far this year. A look at the trailing 12-month EPS for MBRX yields -0.90 with Next year EPS estimates of -0.84. For the next quarter, that number is -0.22. This implies an EPS growth rate of 12.87% for this year and 4.92% for next year.
Float and Shares Shorts:
At present, 29.81 million MBRX shares are outstanding with a float of 28.83 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.19 million, which was 0.62% higher than short shares on Sep 28, 2023. In addition to Mr. Walter V. Klemp as the firm’s Founder, Chairman, President & CEO, Mr. Jonathan P. Foster CPA serves as its Executive VP & CFO.
Through their ownership of 10.23% of MBRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.41% of MBRX, in contrast to 3.28% held by mutual funds. Shares owned by individuals account for 2.81%. As the largest shareholder in MBRX with 3.59% of the stake, The Vanguard Group, Inc. holds 1,070,813 shares worth 1,070,813. A second-largest stockholder of MBRX, Sio Capital Management LLC, holds 271,230 shares, controlling over 0.91% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in MBRX, holding 246,670 shares or 0.83% stake. With a 2.07% stake in MBRX, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 616,108 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.53% of MBRX stock, is the second-largest Mutual Fund holder. It holds 454,705 shares valued at 0.22 million. Fidelity Extended Market Index Fu holds 0.48% of the stake in MBRX, owning 141,909 shares worth 67407.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MBRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With MBRX analysts setting a high price target of $16.00 and a low target of $3.00, the average target price over the next 12 months is $8.00. Based on these targets, MBRX could surge 2611.86% to reach the target high and rise by 408.47% to reach the target low. Reaching the average price target will result in a growth of 1255.93% from current levels.
Summary of Insider Activity:
Insiders traded MBRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 9 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 246,005 while 43,572 shares were sold.